ClinicalTrials.gg

Depressive Disorder, Major clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 3,050 studies for Depressive Disorder, Major across more than 10 countries. 594 are recruiting or about to start. 2,327 of them are mainly about Depressive Disorder, Major (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17.

ClinicalTrials.gov finds 3,677 studies for Depressive Disorder, Major. How that becomes 3,047 here

This page counts the studies the registry files under Depressive Disorder, Major, and those it files under no condition that list Depressive Disorder, Majorthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 3,677Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −154List Depressive Disorder, Major as a condition, but the registry did not file them under itMost often written as “Depression - Major Depressive Disorder” (127), “Major Depression Disorder” (5), and “Major Depressive Disorder With Psychotic Features” (4). The registry filed them under other conditions only, most often Depression (83) and Anxiety Disorders (52).
  3. −476Match it another way166 name it in the title, 7 in a keyword, and 303 by a synonym or other text the search reads.
  4. 3,047The count on this page63 of them list Depressive Disorder, Major in their own words; the registry filed them under no condition.

Status

Completed
1,823
Recruiting
415
Status unknown
240
Terminated
194
Not yet recruiting
150
Withdrawn
97

Phase

Phase 2
520
Phase 3
442
Phase 4
341
Phase 1
216
Early Phase 1
28

Where

United States
1,500
Canada
312
China
207
Germany
164
France
126
United Kingdom
96

Who develops what

Add Depressive Disorder, Major to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 40 programs from 34 companies, 36 with this as their studies’ main aim; 14 with a live phase 3 study; 19 primary completions in the next 12 months. Compare Johnson & Johnson, CSPC Pharmaceutical Group and Neurocrine Biosciences here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
VortioxetineRecent, limited
Evidence
  • NCT07741331 · Chengdu Kanghong Pharmaceutical Group Co., Ltd. · Phase 3 · live · comparator · “Vortioxetine Hydrobromide Tablets” · registered Jul 2026
  • NCT03855865 · AbbVie · Phase 3 · comparator · “Vortioxetine” · registered Feb 2019
H. Lundbeck A/S56% of its industry studiesUS: Takeda (FDA 2013)EU: H. Lundbeck A/S (EMA 2013)11 study
BupropionRecent, limited
Evidence
  • NCT06223880 · Axsome Therapeutics, Inc. · Phase 4 · live · comparator · “Bupropion” · registered Jan 2024
  • NCT04971291 · Axsome Therapeutics, Inc. · Phase 2 · comparator · “Bupropion SR” · registered Jul 2021
  • NCT04388189 · alto neuroscience · Phase 4 · comparator · “Bupropion” · registered May 2020
  • NCT03595579 · Axsome Therapeutics, Inc. · Phase 2 · comparator · “Bupropion” · registered Jun 2018
  • NCT02741791 · Axsome Therapeutics, Inc. · Phase 3 · comparator · “Bupropion” · registered Apr 2016
GlaxoSmithKline28% of its industry studiesUS: off-patent, 31 generics marketed11 study
SertralineRecent, limited
Evidence
  • NCT06827431 · CSPC Pharmaceutical Group Limited · Phase 3 · comparator · “Sertraline” · registered Dec 2024
  • NCT04476030 · Biogen · Phase 3 · background · “Sertraline” · registered Jul 2020
  • NCT01360866 · Otsuka Holdings Co., Ltd. · Phase 3 · background · “Sertraline” · registered May 2011
Viatris Inc.30% of its industry studiesUS: off-patent, 16 generics marketed11 study

11 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
seltorexant☆ Track2 live phase-3 studies: NCT06559306, NCT07573176Johnson & Johnson
azetukalner☆ Track3 live phase-3 studies: NCT07076407, NCT06775379, NCT06922110Xenon Pharmaceuticals Inc.
lumateperoneApproved: US 2019☆ Track2 live phase-3 studies: NCT05850689, NCT07747389Johnson & Johnson
deupsilocin☆ Track2 live phase-3 studies: NCT06793397, NCT06605105Cybin IRL Limited
osavampator☆ Track5 live phase-3 studies: NCT06966401, NCT07196501, NCT06911112Neurocrine Biosciences

The 5 in phase 3 with the nearest primary completion, of 40 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (19)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Dec 2026 est.seltorexant · Johnson & Johnson · Phase 3 main aimNCT06559306 Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms — primary endpoint: Part 1: Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Day 43 · 752 enrolled
  • 31 Dec 2026 est.SPN-821 · Supernus Pharmaceuticals, Inc. · Phase 2 main aimNCT07226661 Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder — primary endpoint: Change From Baseline to Day 29 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. · 230 enrolled
  • 31 Dec 2026 est.Cariprazine Depot, cariprazine · Mapi Pharma Ltd. · Phase 2 named, not the main aimNCT07185815 Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine — primary endpoint: Safety, rate of adverse events (AEs) · 24 enrolled

16 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Depressive Disorder, Major studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here SSRIs 15 open · Serotonin receptor agonists 14 open · Psychedelics 14 open · Antipsychotics 8 open · Inhaled anesthetics 3 open

Coming up

221studies finish main data collection within a year16 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 415 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 295 (71%) stop at 75 or younger. 55 (13%) take children under 18. 11 (3%) are for women only and 1 (<1%) for men only; 99 (24%) take healthy volunteers.

Recruiting studies that take each age, of 415
AgeWomenMen
1012 (3%)12 (3%)
18349 (84%)339 (82%)
30356 (86%)349 (84%)
40354 (85%)347 (84%)
50345 (83%)341 (82%)
65303 (73%)299 (72%)
75134 (32%)131 (32%)
85104 (25%)101 (24%)

Across all 3,050 studies, recruiting or not: 71% stop at 75 or younger and 57% at 65; 9% take children; 4% are for women only and 1% for men only; 20% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Depressive Disorder, Major studies take

Of 196 phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 22 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 116 mo5–45 · 88 studies5 mo1–12 · 40 studies43 mo16–… · 48 studies
Phase 1/236 mo18–75 · 31 studies——
Phase 222 mo14–37 · 196 studies17 mo11–23 · 97 studies35 mo23–57 · 99 studies
Phase 2/346 mo28–56 · 16 studies——
Phase 327 mo21–36 · 124 studies26 mo20–33 · 95 studies—
Phase 435 mo20–58 · 98 studies—44 mo25–60 · 79 studies
Interventional, no phase33 mo17–55 · 693 studies18 mo9–36 · 40 studies34 mo18–55 · 653 studies
Observational38 mo21–67 · 150 studies21 mo14–33 · 29 studies46 mo29–73 · 121 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Newly registered32

Show 27 more

Studies

Recruiting first, then most recently updated. Showing 50 of 3,050. Browse all 3,050 → or search them.